3-Chlorocathinone
Pharmaceutical compound
From Wikipedia, the free encyclopedia
3-Chlorocathinone (3-CC) is a psychostimulant drug of the cathinone family.[1][2][3][4] It is the analogue of the antidepressant and norepinephrine–dopamine reuptake inhibitor (NDRI) bupropion in which the N-tert-butyl group has been removed.[5][3][4] The drug is also the analogue of the stimulant 3-chloromethcathinone (3-CMC; clophedrone) in which the N-methyl group has been removed.[2][3][4]
| Clinical data | |
|---|---|
| Other names | 3-CC; Norclophedrone; 3Cl-C; 3Cl-Cathinone; 3-Chloro-β-ketoamphetamine |
| Drug class | Stimulant; Serotonin–norepinephrine–dopamine releasing agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H10ClNO |
| Molar mass | 183.64 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-CC is a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA).[3][4] Its EC50 values for induction of monoamine release are 64 nM for dopamine, 105 nM for norepinephrine, and 567 nM for serotonin in rat brain synaptosomes.[3][4] Hence, 3-CC shows almost 10-fold preference for induction of dopamine release over serotonin release and around 1.5-fold preference for induction of dopamine release over norepinephrine release.[3][4]
The drug was encountered as a novel designer and recreational drug by 2020.[1]
See also
- 3-Chloro-N-cyclopropylcathinone (3Cl-CpC; PAL-433, RTI-6037-39)